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Because of its potent ability to induce apoptosis, vesicular stomatitis virus (VSV) is an attractive candidate as an oncolytic virus for tumor
therapy. Previous studies have suggested that VSV selectively infects tumor cells due to defects in their antiviral responses making them more
susceptible to VSV infection than normal cells. We tested this hypothesis in the prostate tumor system by comparing LNCaP and PC-3 prostate
tumor cells to benign human prostatic epithelial cells from patient prostatectomy specimens. We compared the cell killing ability of a
recombinant virus containing a wild-type (wt) M protein (rwt) and an isogenic M protein mutant virus (rM51R-M) that induces interferon (IFN)
in infected cells and should display a greater selectivity for tumor cells. Our results showed that in single-cycle infection experiments, LNCaP
cells were sensitive to killing by both wt and mutant viruses, while PC-3 cells were highly resistant to VSV-induced cell killing. LNCaP and
benign prostate cells were similarly susceptible to both viruses, indicating that normal prostate cells are not inherently resistant to killing byVSV.
In each of the cell lines, the rM51R-M virus induced similar levels of apoptosis to rwt virus, showing that the M protein does not play a
significant role in apoptosis induction by VSV in these cells. In multiple-cycle infection experiments, LNCaP cells were more sensitive than
benign prostatic epithelial cells to virus-induced cell killing by rM51R-Mvirus, but not rwt virus. Both viruses were equally effective at reducing
LNCaP tumor volume in vivo following intratumoral and intravenous inoculation in nude mice, while PC-3 tumors were resistant to VSV
treatment. None of the mice treated with rM51R-M virus died as a result of virus infection, while 50–71% of mice treated with rwt virus
succumbed to virus infection. Similarly, when inoculated by themore sensitive intranasal route, the rM51R-Mvirus was less pathogenic than the
rwt virus from which it was derived. These results indicate that M protein mutant viruses are superior candidates as oncolytic viruses for
therapies of prostate tumors, but future strategies for use of VSV will require testing individual tumors for their susceptibility to virus infection.
D 2004 Elsevier Inc. All rights reserved.
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Cytocidal viruses are currently being explored as onco-
lytic agents for anti-tumor therapies (reviewed by Bell et al.,
2003; Giedlin et al., 2003). Vesicular stomatitis virus (VSV)
is an attractive candidate as an oncolytic agent because it is a
potent inducer of apoptosis in infected cells (Balachandran et
al., 2000; Kopecky et al., 2001; Koyama, 1995), and many0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: mahmed@wfubmc.edu (M. Ahmed).types of tumor cells are susceptible to infection and killing by
VSV (Balachandran and Barber, 2000, 2001; Stojdl et al.,
2000, 2003). It has been proposed that the susceptibility of
tumors to VSV and other oncolytic viruses is due to
development of defects in antiviral responses during tumori-
genesis (Balachandran and Barber, 2000, 2001; Bell et al.,
2003; Stojdl et al., 2000, 2003). This may occur because in
many cases, proliferative signaling pathways and antiviral
signaling pathways are mutually antagonistic. Thus, develop-
ment of enhanced proliferative signaling in tumor cells may
lead to suppression of antiviral pathways. For example, it has
been known for many years that most tumor cells are resistant
to the antiproliferative effects of interferons (IFNs) (Einhorn004) 34–49
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IFN signal transduction pathway have been identified in
different types of tumors (reviewed inWong et al., 1997). The
resistance of tumor cells to the antiproliferative effects of
IFNs may make these cells correspondingly more susceptible
to infection with a variety of viruses, including VSV
(Balachandran and Barber, 2000, 2001; Stojdl et al., 2000).
However, it is also possible for tumors to develop resistance
to the antiproliferative effects of IFN without developing
defects in their antiviral responses (Pfeffer et al., 1996).
The idea that cells will develop defects in their antiviral
responses during tumorigenesis is a fundamental principle of
oncolytic virus therapy. However, there are very few
examples in which the susceptibility of tumor cells to virus-
induced killing has been compared directly with that of
normal cells from which they were derived. We chose to ad-
dress this question using human prostate tumors for two
important reasons. First, prostate cancer is the most fre-
quently diagnosed cancer in men and the second leading
cause of cancer-related deaths in the USA (Gotoh et al., 2003;
Polek et al., 2003). No effective therapy is available for
treating prostate cancer once the tumor metastasizes from the
prostate during the course of the disease. Therefore, the
development of novel and effective nonsurgical interven-
tions, such as oncolytic viral therapies, for prostate cancer
would represent a significant advantage for managing pat-
ients with metastatic prostate cancer. Secondly, prostatic epi-
thelial cells derived from benign epithelium can be cultured
from tissues obtained from patients, so that we can assess the
effects of VSV infection on benign cells from the prostate and
compare results to those in prostate tumor cell lines.
If tumor cells are defective in their antiviral responses,
then the selectivity of viruses for tumor cells versus normal
cells can be enhanced by strategies that activate antiviral
responses in normal cells. Indeed, it has been shown that the
selectivity of VSV for tumor cells versus normal cells can be
enhanced either by pretreatment with IFNs or by using VSV
strains that induce IFN production in infected cells (Obuchi et
al., 2003; Stojdl et al., 2000, 2003). Most wild-type (wt)
strains of VSV induce relatively little IFN production in
infected cells. We have shown that this is due to the inhibition
of host gene expression by the viral matrix (M) protein
(Ahmed et al., 2003). The VSVMprotein is a multifunctional
protein that plays a major role in virus assembly as well as in
the inhibition of host gene expression. The inhibition of host
gene expression occurs at multiple levels, including tran-
scription, nuclear-cytoplasmic RNA transport, and trans-
lation (reviewed in Lyles, 2000). This inhibition suppresses
the production of IFNs and other antiviral proteins in infected
cells (Ahmed et al., 2003; Stojdl et al., 2003).
The inhibitory effects of M protein on host gene
expression are genetically separable from its virus assembly
functions, so that a number of different mutations render the
M protein defective in its ability to inhibit host gene
expression without compromising its ability to function in
virus assembly (Ahmed and Lyles, 1997; Ahmed et al., 2003;Black et al., 1993). Viruses containing such M protein
mutations induce IFN production in infected cells (Ahmed et
al., 2003; Francoeur et al., 1987; Marcus et al., 1993; Stojdl et
al., 2003). For the experiments presented here, we compared
a recombinant virus obtained from an infectious cDNA clone
containing a wt M protein (rwt virus) to an isogenic
recombinant containing a single point mutation that sub-
stitutes an arginine for methionine at position 51 of the 229
amino acid M protein (rM51R-M virus). This point mutation
renders the virus defective in its ability to inhibit host gene
expression, but does not compromise the expression of viral
genes or the production of infectious progeny (Ahmed et al.,
2003; Kopecky et al., 2001). According to the basic principle
of oncolytic virus therapy, normal prostatic epithelial cells
should be resistant to the M protein mutant virus due to
activation of antiviral responses, while tumor cells should be
susceptible due to defects in their antiviral responses.
In the experiments presented here, we found that one line
of prostate tumor cells (LNCaP) was susceptible to killing
with VSV, while another line (PC-3) was more resistant,
suggesting that treatment of prostate tumors with oncolytic
VSV will be effective for some, but not all tumors.
Interestingly, benign prostatic epithelial cells were similar
to LNCaP cells in their susceptibility to both wt andMprotein
mutant VSV in single-cycle infection experiments. These
results show that normal prostatic epithelial cells are not
inherently resistant to VSV. Under multiple cycle infection
conditions, benign prostatic cells were resistant to rM51R-M
virus, but not the rwt virus control, while LNCaP cells were
susceptible to both viruses. Thus, activation of antiviral
responses in normal cells by the M protein mutant virus can
prevent virus spread to surrounding uninfected cells. Similar
to cell culture results, LNCaP cells implanted in the flanks of
nude mice were equally susceptible to rwt and rM51R-M
viruses, with complete tumor regression in some cases.
However, while greater than 50% of mice treated with the rwt
virus died due to virus infection, all of the mice treated either
intratumorally or intravenously with rM51R-M virus
remained healthy. Likewise, the rM51R-M virus was less
pathogenic for mice than rwt virus when assayed using the
more sensitive route of intranasal inoculation. These results
indicate that M protein mutant viruses are promising
candidates as oncolytic viruses because of their ability to
spread systemically without causing disease symptoms, and
are safer vectors for tumor therapies due to their ability to
effectively kill tumor cells, while sparing normal tissue.Results
LNCaP and PC-3 prostate cells are differentially responsive
to IFN
Clinical studies indicate that metastatic prostate tumors are
not responsive to IFN treatments (DiPaola and Aisner, 1999;
Tjoa and Murphy, 2000). Therefore, prostate tumors should
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our results indicate that tumor cells derived from the same
tissue vary in their responsiveness to IFN. Fig. 1 illustrates the
differential responsiveness of prostate tumor cells to IFNFig. 2. Interferon bioactivity produced by cells infected with wt and M
protein mutant viruses. LNCaP (triangles), PC-3 (squares), and normal
prostatic (circles) cells were infected with rwt (closed symbols) and rM51R-
M (open symbols) viruses at a multiplicity of 10 pfu/cell for the indicated
times. Supernatants were collected and residual virus was inactivated by
incubation at pH2. HeLa cells were incubated overnight with serial
dilutions of supernatants and were challenged with wt VSV. Cells were
incubated overnight, then fixed and stained with crystal violet. Absorbance
was read at 550 nm on an ELISA reader. The interferon concentration (IU/
ml) was quantitated by comparing results to those in cells incubated with
serial 5-fold dilutions of an interferon standard. Data shown are means for
two independent experiments.
Fig. 1. Responsiveness of LNCaP and PC-3 cells to IFN. LNCaP (A), PC-3
(B), and HeLa (C) cells were incubated with varying concentrations of IFN
(6.4–20000 IU/ml) for 16 h and challenged with wt VSV at an MOI of
0.015 pfu/cell (LNCaP and HeLa cells) or 30 pfu/cell (PC-3 cells). At
various times postinfection, cell viability was measured by MTT assay.
Controls included IFN-untreated cells infected with VSV- and IFN-treated
cells that were not challenged with VSV. Data are expressed as a percentage
of mock-infected cells and are the averages of two separate experiments.using LNCaP and PC-3 cell lines, both of which are derived
from metastatic prostate tumors. LNCaP and PC-3 cells were
seeded onto 96-well dishes and incubated with varying
concentrations of IFN. After 16 h, cells were challenged with
VSVat anMOI of 0.015 pfu/cell for LNCaP cells and anMOI
of 30 pfu/cell for PC-3 cells. The different MOIs used for the
challenge reflect the doses of VSV required to induce
cytopathic effect in each of the cell lines. At different times
postinfection, cell viability was measured by MTT assay.
Cells responsive to IFN should exhibit an IFN dose-depend-
ent resistance to virus infection, while cells that are not
responsive to IFN should show no difference in cytopathic
effect regardless of IFN concentration. HeLa cells were used
as control since they are known to respond to IFN. Data in
Fig. 1A show a decrease in LNCaP cell viability over the time
course of the experiment due to virus infection. Furthermore,
the results indicate that LNCaP cells are not responsive to IFN
since they were not protected from VSV infection by
pretreatment with IFN concentrations as high as 20000 IU/
ml. In contrast, PC-3 cells were responsive to IFN (Fig. 1B)
since close to 100% of cells displayed resistance to VSV
infection upon pretreatment with concentrations of IFNz800
IU/ml. The sensitivity of PC-3 cells to IFN was similar to that
observed with HeLa cells (Fig. 1C). These results indicate
that prostate tumor cells can differ dramatically in their
response to IFN and suggest that they may also be different in
their sensitivity to oncolytic VSV.
We have previously generated recombinant M protein
mutants of VSV that are defective in their ability to suppress
IFN production by infected cells (Ahmed et al., 2003). Our
original hypothesis was that these mutant viruses would be
defective in their ability to replicate in normal cells or in IFN-
responsive tumor cells like PC-3 cells, but should replicate
well in tumor cells that have defects in their IFN responses,
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determined the ability of benign prostate epithelial cells
compared to prostate tumor cells to produce IFN in response
to infection with isogenic recombinant viruses containing wt
(rwt virus) or mutant M protein (rM51R-M virus).
Primary cultures of normal human prostate epithelial cells
were obtained from a benign region of the prostate peripheralFig. 3. Single-cycle infection of prostate tumor and benign cells with wt and M pr
and WFU55PZ benign prostate (C) cells infected with rwt and rM51R-M viruses. T
determined by flow cytometry analysis of LNCaP, PC-3, and normal prostate ce
rM51R-M viruses at a multiplicity of 10 pfu/cell for 4 and 8 h. After infection,
antibody conjugated to fluorescein. G protein cell surface fluorescence was quantit
a percentage of total cells with fluorescence above the negative control mock-infect
Single-cycle virus growth analysis in LNCaP (D), PC-3 (E), and WFU55PZ (F) cel
cell. A small aliquot of the supernatant was removed at the indicated times postinfe
average of two independent experiments.zone of a patient prostatectomy specimen (WFU55PZ strain).
These cultures have been extensively characterized to be
representative of normal human epithelial cells as described
in Materials and methods. WFU55PZ cells, LNCaP cells, or
PC-3 cells were infected with either rwt or rM51R-M virus,
and IFN released into the media was assayed at varying
times postinfection. IFN levels were determined by aotein mutant viruses. G protein surface expression in LNCaP (A), PC-3 (B),
he efficiency of G protein cell surface expression during VSV infection was
lls infected with wt and mutant viruses. Cells were infected with rwt and
cells were labeled with anti-G protein antibody followed by a secondary
ated with a flow cytometer. The surface expression of G protein is shown as
ed cells. Data shown are the meanF SEM of four independent experiments.
ls. Cells were infected with wt and mutant viruses at a multiplicity of 10 pfu/
ction to determine the amount of progeny virus by plaque assay. Data are the
Fig. 4. Induction of DNA fragmentation in LNCaP (A), PC-3 (B), and
WFU55PZ (C) cells infected with rwt and rM51R-M viruses. Cells were
infected with wt and mutant viruses at a multiplicity of 10 pfu/cell. At 24
and 48 h postinfection, cells were harvested, fixed, and permeabilized. Cells
were incubated with the TUNEL reaction mixture according to the
manufacturer’s directions, and the incorporated fluorescein was analyzed
and quantitated by flow cytometry. Data are expressed as the percentage of
total cells undergoing apoptosis and are the means F SD of four
experiments.
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HeLa cells in the presence of supernatants from infected
prostate cells (Fig. 2). Infection with rM51R-M virus
induced IFN production in all three cell types (open
symbols). In contrast, no IFN bioactivity was detectable in
cells infected with rwt virus (closed symbols). These results
are consistent with earlier data showing that M protein
mutant viruses induce IFN production, while viruses with
wt M protein suppress IFN production by infected cells.
Although both benign cells (open circles) and PC-3 cells
(open squares) produced substantial levels of IFN, PC-3
cells actually produced slightly higher levels of IFN than
benign prostate cells, indicating that the production of IFN
in tumor cells can actually be greater than that in the normal
cells from which they were derived. LNCaP cells produced
low, but detectable levels of IFN following infection with
rM51R-M virus (open triangles). Collectively, the results in
Figs. 1 and 2 with LNCaP cells are generally consistent with
the idea that tumor cells have less effective antiviral
responses than corresponding normal cells, but the results
with PC3 cells show that prostate tumor cells can differ
dramatically in their antiviral responses.
PC-3 cells are more resistant than LNCaP and benign
prostate cells to infection with wt and mutant viruses under
single-cycle infection conditions
To determine whether the sensitivity of tumor and benign
prostate cells to VSV infection correlates with their IFN
responses, we tested the ability of rwt and rM51R-M viruses
to infect LNCaP and PC-3 tumor cells as well as benign
prostate cells in single-cycle infection experiments. Cells
were infected at a multiplicity of 10 pfu/cell, so that in theory,
nearly 100% of cells were infected. The efficiency of
infection was measured by determining the percentage of
cells expressing the viral G protein surface antigen by flow
cytometry at 4 and 8 h postinfection, and by determining
yields of progeny virus by plaque assay over a 48 h time
course (Fig. 3). As expected from the low levels of their
antiviral responses, LNCaP cells were highly susceptible to
VSV infection, with nearly 100% of cells expressing G
protein at the cell surface by 8 h postinfection, and production
of progeny virus at approximately 108 pfu/ml by 12 h
postinfection (Figs. 3A and D). There was little difference
between rwt and rM51R-M viruses in their ability to produce
infectious progeny in LNCaP cells, with theM protein mutant
virus producing slightly higher titers than its isogenic wt
control. This result is consistent with our earlier data in other
cell types showing that the M51R M protein mutation has
little effect on the virus assembly function of M protein, and
that the rM51R-M virus produces slightly higher virus yields
than rwt virus (Ahmed et al., 2003).
In contrast to LNCaP cells, infection of PC-3 cells with
VSV was much less efficient, with only 10–20% of cells
expressing G protein above background levels by 8 h post-
infection, and production of lower levels of progeny virusover a longer time course (Figs. 3B and E). It appeared that
a slightly lower percentage of PC-3 cells infected with
rM51R-M virus expressed G protein on their surface than
cells infected with rwt virus. However, the yields of infectiQ
ous progeny of the two viruses were nearly indistinguishable,
despite the fact that the M protein mutant virus induced
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did not (Fig. 2). These results suggest that the relative resistQ
ance of PC-3 cells to VSV infection under single-cycle condiQ
tions is due to antiviral factors in addition to IFN responses.
To our surprise, the results obtained with benign prostate
cells under single-cycle infection conditions were more
similar to those in LNCaP cells than PC-3 cells. Seventy to
ninety percent of WFU55PZ cells infected with the rwt virus
expressed the viral G protein (Fig. 3C). Cells infected with
rM51R-M virus expressed G protein to a slightly lesser extent
(50–60% of cells) than cells infected with rwt virus, although
this difference was not statistically significant. Likewise,
there was little if any difference between rwt and rM51R-M
viruses in yield of infectious progeny from WFU55PZ cells
(Fig. 3F). The time course of virus production by WFU55PZ
cells was intermediate between those of LNCaP and PC-3
cells. These results show that the generalization that tumor
cells are more susceptible to virus infection than normal cells
is not always true. In the case of the prostate, normal epithelial
cells are quite susceptible to VSV infection. Some tumor
cells, such as LNCaP, are even more susceptible, while
others, such as PC-3 cells, are more resistant.
M protein mutation has little effect on VSV-induced
apoptosis in prostate cells
A crucial question for tumor therapy is whether M
protein mutant viruses induce apoptosis in infected prostateFig. 5. Cell viability of prostate tumor and benign cells infected with wt and mu
WFU55PZ (C), and WFU232BPH (D) cells were infected with wt and mutant viru
cells were measured by MTT assay. Data are expressed as a percentage of the cell v
experiments.cells, since M protein mutants are delayed in their
induction of apoptosis in some cell types (Kopecky et
al., 2001). Furthermore, it is important to determine
whether prostate cancer cells are differentially susceptible
to apoptosis induction by VSV. Therefore, the percentage
of cells undergoing DNA fragmentation characteristic of
apoptotic cells was determined by TUNEL assay. LNCaP,
PC-3, and WFU55PZ cells were infected with rwt and
rM51R-M viruses at an MOI of 10 pfu/cell. At 24 and 48
h postinfection, cells were fixed, permeabilized, and
incubated with a TUNEL reaction mixture containing a
fluorescent label, and the percentage of cells containing
DNA strand breaks was determined by flow cytometry. At
24 h postinfection, a higher percentage of LNCaP cells
infected with the rM51R-M virus was apoptotic as
compared to cells infected with the rwt virus (Fig. 4A,
white bars). However, at 48 h postinfection, there was no
difference between cells infected with wt and rM51R-M
viruses (black bars). In contrast to LNCaP cells, a lower
percentage of PC-3 cells (5–10%) infected with wt and
mutant viruses was apoptotic by 48 h postinfection (Fig.
4B). However, there was detectable apoptosis at day 7
postinfection (hatched bars). WFU55PZ cells were also
susceptible to apoptosis induced by both wt and mutant
viruses (Fig. 4C), but not to the same degree as LNCaP
cells. These results indicate that LNCaP and PC-3 prostate
tumor cells vary in their sensitivity to VSV-induced
apoptosis. However, the M protein mutant virus was astant viruses under single-cycle infection conditions. LNCaP (A), PC-3 (B),
ses at a multiplicity of 10 pfu/cell. At the indicated times postinfection, live
iability of mock infected cells and represent the meansF SD of three or four
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prostate cells. Thus, M protein plays little if any role in the
induction of apoptosis in these cells.
The ability of wt and M protein mutant viruses to kill
prostate tumor and benign cells was confirmed by MTT
assay. These experiments compared LNCaP, PC-3, and
WFU55PZ cells, and another benign prostate cell strain
isolated from a patient with benign prostatic hyperplasia,
WFU232BPH. Cells were infected at an MOI of 10 pfu/
cell with rwt and rM51R-M viruses, and cell viability
was measured at different times postinfection (Fig. 5).
Results show that LNCaP cells were sensitive to killing
by wt and mutant viruses and that there was no
difference between wt and mutant viruses in their ability
to kill these cells (Fig. 5A). Consistent with DNA
fragmentation data shown in Fig. 4, PC-3 cells wereFig. 6. Multiple cycle infection of LNCaP and benign prostate cells with wt and M p
and WFU55PZ (B) cells. Cells were infected with wt and mutant viruses at a multi
indicated times postinfection to determine the amount of progeny virus by plaque a
LNCaP (C), WFU55PZ (D), andWFU232BPH (E) cells infected with wt and mutan
was measured by an MTT assay. Data are expressed as a percentage of the cell via
experiments.resistant to killing by VSV (Fig. 5B). However, viability
of cells infected with wt and mutant viruses decreased by
day 7 postinfection. WFU55PZ benign prostatic epithelial
cells were sensitive to killing by each of the viruses so
that by 48 h postinfection, approximately 20% of infected
cells remained viable (Fig. 5C). These results were also
consistent with apoptosis data obtained in Fig. 4C.
WFU232BPH cells were somewhat more resistant to
virus-induced cell killing, with approximately 40% of
cells remaining viable at 72 h postinfection (Fig. 5D).
Despite this difference between prostate cells from
different patients, we can conclude from Figs. 3, 4, and
5 that LNCaP prostate tumor and benign cells are
susceptible to infection and killing with wt and mutant
viruses under single-cycle infection conditions, while PC-
3 cells are more resistant. Furthermore, these resultsrotein mutant viruses. Multiple cycle growth analysis of virus in LNCaP (A)
plicity of 0.1 pfu/cell. A small aliquot of the supernatant was removed at the
ssay. Data are the average of two independent experiments. Cell viability of
t viruses. Cells were infected at a multiplicity of 0.1 pfu/cell and cell viability
bility of mock-infected cells and represent the means F SD of three or four
Fig. 7. Treatment of LNCaP tumors with rwt and rM51R-M viruses.
LNCaP cells were injected subcutaneously in the flank of BALB/c nude
mice. Animals with palpable tumors were randomly separated into three
experimental groups (4–5 animals/group) and were injected in the tumor
with 1  108 pfu of rwt (n = 7) or rM51R-M (n = 10) viruses in culture
medium or with culture medium alone (n = 7) as a negative control. Tumor
volume was measured daily with calipers. Animals showing symptoms of
end-stage VSV infection or signs of terminal illness were sacrificed and the
tumor and selected tissues (brain, lungs, spleen, and liver) were harvested
for histology. (A) Data represent three separate experiments and are shown
as the percentage of original tumor size on day 0 (mean F SD). (B)
Histological examination of tumors by routine hematoxylin and eosin
staining.
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role in VSV-induced apoptosis in the prostate.
Benign prostate cells are more resistant to infection with
M51R-M virus than wt viruses in multiple-cycle infection
experiments
To determine whether antiviral responses in infected cells
affect spread of virus to surrounding uninfected cells, we
tested the ability of wt and mutant viruses to infect LNCaP
and benign prostate cells under multiple-cycle infection
conditions (MOI = 0.1 pfu/cell). Similar to data obtained
under single-cycle infection conditions, rM51R-M grew to
titers slightly higher than those of rwt virus in LNCaP cells in
the multiple-cycle growth experiment (Fig. 6A). Although
both viruses reached titers as high as those observed in the
single-cycle growth experiment (Fig. 3D), there was a delay
in growth due to differences in kinetics of virus spread. This
delay was also seen in WFU55PZ cells infected with each of
the viruses (Fig. 6B). However, in contrast to LNCaP cells,
the rM51R-M virus produced lower levels of infectious virus
progeny than rwt virus in WFU55PZ cells. In fact, by 96 h
postinfection, rM51R-M virus titers were 2 logs lower than
those of rwt virus. Similar data were obtained from
WFU232BPH benign prostate cells (data not shown). These
data suggest that the elevated antiviral response in benign
prostate cells infected with rM51R-M virus limits virus
spread to surrounding cells.
The ability of wt and mutant viruses to kill LNCaP and
benign prostate cells under multiple-cycle infection con-
ditions was measured by MTT assay. Data indicate that
LNCaP cells were equally susceptible to killing by both of
the viruses (Fig. 6C). However, both isolates of benign
prostate cells were highly resistant to cell killing by rM51R-
M virus. Close to 90% of benign prostate cells infected with
rM51R-M virus retained viability at 96 h postinfection
(Figs. 6D and E). In contrast, both cell strains were sensitive
to killing by rwt virus. As expected from single-cycle
experiments, PC-3 cells remained resistant to killing by wt
and mutant viruses under multiple-cycle infection condi-
tions (data not shown). These results indicate that in contrast
to data obtained in the single-cycle experiments, primary
cultures of benign prostate cells are consistently resistant to
infection with rM51R-M virus in multiple-cycle infection
experiments, likely due to the ability of this virus to induce
an effective antiviral response in these cells as compared to
LNCaP cells.
Rwt and rM51R-M viruses effectively kill LNCaP tumor
cells in vivo
To compare the ability of rwt and rM51R-M viruses to
kill prostate tumor cells in vivo, LNCaP and PC-3 cells were
injected subcutaneously in the flanks of BALB/c nude mice,
and when palpable tumors were obtained, mice were treated
with rwt and rM51R-M viruses. Tumor-bearing mice were
M. Ahmed et al. / Virology 330 (2004) 34–4942injected either intratumorally (Fig. 7A) or intravenously
(Fig. 8A), and tumor volume was measured daily. LNCaP
tumor volume decreased in animals treated intratumorally
with both rwt and rM51R viruses, while mock-treated
tumors continued to increase in size (Fig. 7A). By 2 weeks
posttreatment, the tumors of mice injected with rM51R-M
virus had decreased to approximately 40% of their initial
volume at the start of the experiment. In fact, after day 14,
the percent change in volume of tumors treated with
rM51R-M virus (mean percent decrease = 60.6) was
significantly lower than rwt virus (mean percent decrease
37.4) treated tumors (P = 0.048). Interestingly, although the
tumors of mice treated with rwt virus also regressed, some
tumors started to increase in size again by 10 days
posttreatment. Statistical analysis indicated that tumors
treated with rwt virus did not decrease further between
days 7 and 14 (P = 0.68), whereas tumors treated withFig. 8. Tumors derived from PC-3 cells are resistant to treatment with wt and mut
flank of BALB/c nude mice. When palpable tumors had formed, animals were inj
medium or with culture medium alone as a negative control. Four animals per grou
used for PC-3 tumor experiments. Data are shown as the percentage of original t
LNCaP and PC-3 tumors from mice treated with rwt virus.rM51R-M virus significantly decreased (P = 0.0014) during
that time.
Histological examination of tumors by hematoxylin and
eosin (H and E) staining at day 14 postinfection showed that
mock-infected tumor cells had well-defined cell borders and
hyperchromatic nuclei (Fig. 7B). The cytoplasm of these cells
was vesicular and eosinophilic, with evidence of mitoses. In
contrast, tumors treated with rwt and rM51R-M viruses were
extensively necrotic, characterized by loss of nuclear stain-
ing, increased cytoplasmic eosinophilia, and loss of cellular
detail and cell borders. The additional tissue eosinophilia in
tumors infected with rM51R-M virus was due to infiltrating
erythrocytes as a result of hemorrhaging. These data support
the idea that the remaining tumor mass at day 14 consisted
largely of dead or dying tumor cells.
Results similar to those obtained in Fig. 7A were
observed when LNCaP tumor-bearing animals were sys-ant viruses. (A) LNCaP and PC-3 cells were injected subcutaneously in the
ected intravenously with 2  107 pfu of rwt or rM51R-M viruses in culture
p were used for LNCaP tumor experiments, and two animals per group were
umor size on day 0 (mean F SD). (B) Viral antigen staining in sections of
Fig. 9. Determination of the median lethal dose (LD50) for BALB/c mice
infected with wt and M protein mutant viruses. Six-week-old BALB/c male
mice (Charles River) were intranasally infected with the indicated titers of
wtO, rwt, and rM51R-M viruses (102–108 pfu/mouse) under light
anesthesia. Mice were monitored daily for signs of VSV infection, such
as hind limb paralysis, decreased locomotion, and weight loss. Upon signs
of end-stage illness, mice were euthanized and organs (brain, liver, spleen,
lungs) were collected for histological analysis. (A) The percentage survival
of mice infected with varying doses of wtO, rwt, or rM51R-M viruses. Two
separate experiments were carried out using five mice per group. (B)
Weight of mice infected with rwt and rM51R-M viruses. The weight of
mice was measured 3 weekly following infection with 106 pfu of rwt and
rM51R-M viruses. The experiment included five mice per group. (C) Virus
titers in tissues of infected mice. Mice were intranasally inoculated with 106
pfu of rwt and rM51R-M viruses. At day 7 postinfection, animals were
sacrificed, and organs (brain and lungs) were collected for determination of
viral titers by plaque assay. Data represent the mean titer F SD of 2–3
mice.
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symbols). By day 7 posttreatment, tumors of mice injected
with each of the viruses decreased to approximately 60% of
their initial volume, and further decreased to approximately
50% of their initial volume by 2 weeks posttreatment. As
expected from the results of tissue culture experiments, PC-
3 tumors (closed symbols) were highly resistant to treatment
with either rwt or rM51R-M virus and continued growing in
size at a rate similar to mock-treated tumors. Immunohis-
tochemical analysis of tumors from mice at day 14 (PC-3
tumors) and day 15 (LNCaP tumors) posttreatment was
carried out with antibodies against the viral G protein to
determine the ability of each of the viruses to replicate and
spread in the tumor tissue (Fig. 8B). Viral antigen was
detected at high levels in LNCaP-derived tumors, with
evidence of extensive cell killing. In contrast, much fewer
cells were positive for viral antigen in PC-3 tumors, and the
cells remained healthy. These data further support the idea
that prostate tumors vary in their sensitivity to treatment
with VSV.
The M protein mutant virus is less pathogenic than viruses
with wt M proteins
Although there was little if any difference between
rM51R-M and rwt viruses in their effects on tumors, there
was a striking difference in the morbidity of treated mice.
Seventy-one percent of mice treated intratumorally and 50%
of mice treated systemically with the rwt virus showed severe
symptoms of VSV infection, including paralysis, weight loss,
and disorientation, ultimately leading to death between days 7
and 14. However, none of the mice treated with rM51R-M
virus showed signs of illness and there was complete
elimination of tumors by 6–8 weeks in some cases.
To confirm differences in pathogenesis exhibited
between rwt and rM51R-M viruses following treatment, 5-
week-old male BALB/c mice were inoculated with varying
doses of these viruses by the intranasal route, which is a
more sensitive indicator of viral pathogenesis. Studies have
shown that VSV can enter the brain through the olfactory
tract, resulting in an acute infection of the CNS (Huneycutt
et al., 1993, 1994). Mice were monitored daily for hind-limb
paralysis, weight loss, and other signs of illness. Mice
showing signs of terminal illness were euthanized and
scored as nonsurvivors according to AAALAC recommen-
dations. Organs were collected for immunohistochemistry
and plaque assay to determine spread of virus. As a control
for these experiments, we included a naturally occurring wt
strain of VSV (Orsay strain) since earlier data had suggested
that recombinant strains of VSV might be less pathogenic
than naturally occurring strains.
Illness was observed in mice infected with both wtO and
rwt viruses. The LD50 of the wtO strain was between 10
3
and 104 pfu (Fig. 9A). The percent survival of mice
inoculated with rwt virus was significantly higher than
mice infected with wtO virus (P = 0.021) with a LD50between 105 and 106 pfu. Interestingly, few mice infected
with rwt virus displayed signs of hind-limb paralysis.
Instead, these mice exhibited other signs of illness such as
weight loss, decreased locomotion, and disorientation,
ultimately leading to death. In addition, mice infected with
rwt virus succumbed to infection at least 2–3 days after the
mice that were infected with wtO virus (data not shown). In
contrast, all mice infected with rM51R-M virus, with doses
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experiment (Fig. 9A). Statistical analysis indicated that the
rM51R-M virus was significantly less pathogenic than both
rwt (P = 0.0053) and wtO (P b 0.0001) viruses.
Furthermore, these mice showed no signs of illness as
indicated by a lack of weight loss (Fig. 9B) for at least 2
months, at which time they were sacrificed. In contrast, all
mice infected with rwt virus showed signs of illness as
indicated by statistically significant weight loss from day 6
postinfection as compared to mice infected with rM51R-M
virus.
Viral titers in brain and lung collected from mice at day 7
postinfection were determined to analyze the presence of
infectious virus in infected animals (Fig. 9C). Although we
were unable to detect infectious virus in the lungs of VSV-
infected mice at these times, brains of mice infected with
each of the viruses had detectable levels of infectious virus.
However, viral titers from the brains of rwt-infected mice
were 4 logs lower than those obtained from brains of mice
infected with wtO virus. Furthermore, brains of mice
infected with rM51R-M virus had the lowest levels of
infectious virus. These data indicate that although the
rM51R-M virus was able to spread to the brain, it was less
pathogenic than viruses containing wt M proteins.Discussion
One of the underlying assumptions in the use of VSV as
an oncolytic virus is that tumor cells have defective antiviral
responses compared to the normal cells from which they
were derived. Prostate tumors provide an excellent oppor-
tunity to test this hypothesis since prostate tumor cells, such
as LNCaP and PC-3 cells, can be compared to benign
prostate epithelial cells cultured from patient tissues. Results
in this paper demonstrated that LNCaP cells were sensitive
to infection and killing by VSV, while PC-3 cells were
highly resistant in cell culture (Figs. 4 and 5). Furthermore,
similar results were obtained upon VSV treatment of
LNCaP and PC-3 tumor-bearing mice (Fig. 8). PC-3 cells
were able to produce high levels of IFN (Fig. 2) and respond
to the antiviral effects of IFN (Fig. 1), while LNCaP cells
were not responsive to IFN. This difference may account in
part for the resistance of PC-3 cells to VSV. Although this is
an attractive hypothesis, our results indicate that the IFN-
inducing rM51R-M virus grew to levels comparable to those
of rwt virus in PC-3 cells (Fig. 3E). Therefore, the
overexpression of IFN in rM51R-M virus-infected PC-3
cells does not activate an antiviral response to selectively
attenuate rM51R-M virus infection. Based on these data, it
is likely that antiviral factors other than or in addition to
those activated by the IFN response pathway contribute to
the resistance of PC-3 cells to VSV infection and killing.
Despite the fact that LNCaP and PC-3 cells are both derived
from metastatic prostate tumors, numerous molecular differ-
ences between these two cell types have been described(Payaloor et al., 1999; Polek et al., 2003; Yang et al., 2003).
Our future experiments will determine whether previously
observed differences in these tumor cells are responsible for
their differential susceptibility to VSV. Furthermore, addi-
tional candidate genes that are differentially regulated in
these VSV-sensitive and -resistant cell lines will be
identified by microarray comparisons.
It has generally been accepted that normal cells are more
resistant to VSV-induced cytopathic effects than tumor cells
(Obuchi et al., 2003; Stojdl et al., 2000). However, our data
show that prostate epithelial cells are not inherently resistant
to VSV infection, since both viruses produced infectious
progeny and killed benign prostatic epithelial cells as well
as LNCaP cells in single-cycle infection experiments (Figs.
4 and 5). These results are similar to those in mouse embryo
fibroblasts that exhibit some susceptibility to VSV infection
(Obuchi et al., 2003; Stojdl et al., 2003), but contrast with
those in rat hepatocytes that appear to be nonpermissive for
VSV growth (Ebert et al., 2003). The ability of VSV to
infect benign prostate cells should not be a concern for the
use of this virus for prostate tumor therapy, since normal
prostatic tissue is surgically removed as part of the therapy.
Furthermore, our results also show that the rM51R-M virus
induced high levels of IFN production in benign prostate
cells while the rwt virus did not (Fig. 5). In contrast to data
obtained in single-cycle experiments, multiple-cycle infec-
tion experiments indicate that benign prostate cells are
resistant to infection with rM51R-M virus (Figs. 6D and E),
but not rwt virus, supporting the idea that the M protein
mutant virus induces an effective antiviral response in
infected benign prostate cells, thereby protecting surround-
ing uninfected cells from VSV-induced cell killing.
One of the principal cytopathic effects of VSV infection
is the potent activation of apoptosis, which is the basis for
its oncolytic activity. Recent studies from our laboratory
have shown that at least two viral components are involved
in the induction of apoptosis by VSV, M protein, and
another viral product(s) that has not been identified
(Kopecky et al., 2001). It was important to determine the
relative importance of M protein for the induction of
apoptosis in prostate tumor cells, because the role of M
protein in the regulation of apoptosis during a virus
infection is dependent on cell type. Studies with rwt and
rM51R-M viruses have shown that in some cell types, such
as HeLa cells, the wt M protein accelerates VSV-induced
apoptosis (Kopecky et al., 2001). This is due to the ability of
wt M protein to inhibit host gene expression, which rapidly
induces apoptosis through activation of the mitochondrial
pathway in these cells (Kopecky and Lyles, 2003). How-
ever, in other cell types, such as BHK cells, the rM51R-M
virus induces apoptosis more rapidly than rwt virus,
indicating that another viral product is the major inducer
of apoptosis in these cells (Kopecky and Lyles, 2003;
Kopecky et al., 2001). Experiments presented here show
that there was no difference between rwt and rM51R-M
viruses at inducing apoptosis in LNCaP and PC-3 prostate
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and B). Similar results were seen in benign prostate cells
infected with these viruses (Fig. 4C). These data indicate
that the M protein plays little role in inducing apoptosis in
VSV-infected prostate cells.
Laboratory strains of VSV have little if any pathogenicity
for healthy adult humans (Richmond and McKinney, 1999).
However, the potential for VSV to cause disease in cancer
patients who may be immunocompromised has not been
explored. Previous studies testing the effectiveness of VSV
as an oncolytic virus have shown that immunocompromised
mice are highly susceptible to lethal infection with wt VSV
strains (Huneycutt et al., 1993; Stojdl et al., 2000). Since
one of the main concerns regarding the use of viral vectors
for tumor therapies is their safety in patients, our goal was to
develop viruses based on VSV that were less pathogenic
than their wt counterparts. Therefore, our idea was that IFN-
inducing viruses, such as rM51R-M virus, would be safer in
vivo due to their inability to suppress an effective antiviral
response in normal tissue. Indeed, our data show that
rM51R-M and rwt viruses were equally effective in
reducing LNCaP tumor burdens in nude mice (Figs. 7 and
8), but rM51R-M virus had a dramatically reduced
pathogenicity in both nude mice and immunocompetent
mice (Figs. 7, 8, and 9). These results support our
hypothesis that M protein mutant viruses would not only
be effective oncolytic viruses for prostate tumor therapy due
to their ability to kill tumor cells, but would also be safer
viruses due to their ability to induce antiviral responses and
spare normal cells. Similar strategies for enhancing the
safety of VSV vectors include pretreating mice with IFN
(Stojdl et al., 2000), engineering an IFN gene into the VSV
genome (Obuchi et al., 2003), and using naturally occurring
IFN-inducing mutants of VSV (Stojdl et al., 2003).
Several studies have demonstrated the effectiveness of
VSV as an oncolytic agent for anti-tumor therapies in
experimental animals with a variety of tumor types
(Balachandran and Barber, 2000, 2001; Ebert et al., 2003;
Huang et al., 2003; Obuchi et al., 2003; Stojdl et al., 2000,
2003). These tumors include p53-null C6 glioblastomas
(Balachandran and Barber, 2001), myc and ras transformed
cell lines (Balachandran and Barber, 2001), and human
melanoma xenografts (Stojdl et al., 2000) in nude mice. In
addition, VSV represses the growth of several different
metastatic tumor models in immunocompetent mice (Huang
et al., 2003; Obuchi et al., 2003; Stojdl et al., 2003) and
hepatocellular carcinomas in rats (Ebert et al., 2003). Our
results with the treatment of prostate tumor xenografts are
consistent with these previous studies (Figs. 7 and 8). The
effectiveness of VSV in reducing tumor volume varies
considerably among these different tumor models. Our
results showing that a single treatment of a well-established
tumor derived from LNCaP cells with rM51R-M virus led to
complete tumor regression in some cases without causing
disease in nude mice stands among the most successful
examples. One of the key issues in the treatment of prostatetumors will be the ability to treat widespread metastatic
tumors. In this regard, systemic treatment by intravenous
inoculation with VSV has been shown to be as effective as
intratumoral inoculation in different tumor systems (Bala-
chandran and Barber, 2001; Stojdl et al., 2003), and we have
confirmed this result with rM51R-M virus treatment of
LNCaP cells (Figs. 7 and 8). This reflects the ability of VSV
to spread systemically and seek out the tissues that are
susceptible to virus infection (Reiss et al., 1998).
The fact that mice bearing tumors derived from PC-3
cells were resistant to treatment with VSV indicates that
VSV is not effective at treating all prostate tumors (Fig. 8).
Thus, any future strategy for using VSV for prostate tumor
therapy is likely to involve testing individual tumors for
their susceptibility to virus infection. We are in the process
of analyzing patient tumors for their susceptibility to VSV
infection and killing. Our preliminary results show that
primary cultures from tumor regions of human prostatec-
tomy specimens exhibit a phenotype intermediate between
that of LNCaP and PC-3 cells in their susceptibility to VSV
infection and apoptosis. Therefore, it is possible that
prostate tumors isolated from patients exhibit a range of
sensitivity to VSV infection and killing. Future studies will
allow us to determine the degree of differences present in
prostate tumors and develop viruses that will more success-
fully treat such tumors.
Previous experiments to determine the efficacy of VSV
as a vector for anti-tumor therapies used naturally occurring
wt and mutant strains of VSV in mice (Balachandran and
Barber, 2000, 2001; Stojdl et al., 2000, 2003). In this study,
we tested the effectiveness of less pathogenic recombinant
strains of VSV as agents for prostate tumor therapy. The
recombinant background resulted in a significantly less
pathogenic virus than the laboratory adapted wtO virus (Fig.
9A) and therefore offers great promise as a backbone from
which additional viral vectors will be constructed. Further-
more, although LNCaP tumor volume in rwt virus-treated
mice decreased over time similar to results obtained in mice
treated with rM51R-M virus (Figs. 7 and 8), it is possible
that in certain cases rM51R-M virus may be prematurely
cleared by the host before it can effectively spread to distal
tumor sites. Therefore, our future studies will include
incorporating M protein mutations in the virus that would
confer varying degrees of pathogenicity in animals. These
M protein mutant viruses would further be analyzed as
potential vectors for therapies of tumor that may be more
resistant to rM51R-M virus. One such M protein mutation is
the N163D substitution that is conserved in a heterogeneous
viral population from persistently infected cells (Ahmed and
Lyles, 1997). The N163D M protein exhibits an intermedi-
ate phenotype between wtO M protein M51R-M in its
ability to inhibit host gene expression (Ahmed and Lyles,
1997). By testing viruses with such mutations, this will
allow us to determine the balance necessary between viral
and host factors for the development of recombinant viruses
for effective tumor therapies.
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Cells and viruses
LNCaP and PC-3 tumor cells were from the American
Type Culture Collection and were grown in RPMI 1640
containing 10% FBS. Primary human prostatic epithelial
cells were isolated from prostatectomy specimens at Wake
Forest University School of Medicine by modification
(Barreto et al., 2000; Rao et al., 2002) of the method of
Peehl (1992) and Peehl et al. (1988). Briefly, a small piece
of tissue from each specimen was removed using a sterile
cork borer. The prostatectomy specimen was inked with a
color-coded scheme to trace the pathological origin of the
culture specimen. The tissue plug was minced with scissors
and a sterile razor blade and digested overnight with 40–60
U collagenase/ml of medium PFMR-4A plus growth factors
and hormones. To remove the majority of the stromal cells,
the tissue was rinsed twice with 5 ml HEPES-buffered saline
(HBS) and centrifuged. The digested tissue was inoculated
into a 60-mm tissue culture dish coated with collagen type I
(Vitrogen 100, Cohesion, Palo Alto, CA) and grown in
medium PFMR-4A supplemented with growth factors and
hormones. The cells that grew out from the tissue were
aliquoted and stored in liquid nitrogen. Adjacent tissue
blocks were used to determine the pathological origin of the
culture. Only samples greater than 95% of a particular
histological type (i.e., benign or cancer) were used.
Heterogeneous specimens were not used. The frozen
aliquots were thawed to produce secondary cultures, which
were grown in medium MCDB 105 supplemented with
growth factors and hormones (Peehl, 1992; Peehl et al.,
1988). Prostatic epithelial cells derived by these methods are
designated as normal prostatic epithelial cells due to their
inability to form tumors or benign structures in xenograft
models, and due to the lack of cytogenetic abnormalities that
are found in cells derived from cancer areas of the prostate.
In addition, these cells were tested for 1alpha hydroxylase,
whose expression is reduced in tumor cells.
Nomenclature for prostatic epithelial cell strains is
bWFUQ followed by the strain number (in serial order of
acquisition) and then the histology of origin (PZ, peripheral
zone; BPH, benign prostatic hyperplasia).
Wild-type VSV (Indiana serotype, Orsay strain) was
grown in BHK cells as described previously (Lyles and
McKenzie, 1997). The recombinant viruses, rwt and
rM51R-M, were isolated from infectious VSV cDNA clones
and virus stocks were prepared in BHK cells as described
(Kopecky et al., 2001).
Responsiveness to IFN
LNCaP, PC-3, and HeLa cells were plated onto 96-
well dishes and pretreated with different concentrations of
IFN (6.4–20000 IU/ml). Cells were incubated overnight
and challenged with wtO virus at an MOI of 0.015 pfu/cell for LNCaP and HeLa cells, and an MOI of 30 pfu/
cell for PC-3 cells. It was important to use different
MOIs for PC3 cells in order to obtain cytopathic effects
within the time scale of the assay. Furthermore, the use
of 96-well dishes rather than 6-well dishes was important
for optimizing this assay. At varying times postinfection,
live cells were measured by an MTT assay (Cell
Proliferation Kit 1; Roche Diagnostics, Indianapolis, IN)
for cell viability. Controls included IFN-untreated cells
infected with VSV and IFN-treated cells that were not
challenged with VSV. Data are the averages of two
separate experiments.
Interferon bioassay
To determine the IFN activity produced by cells infected
with wt and mutant viruses, supernatants (100 Al) were
collected from LNCaP, PC-3, and benign prostate cells
infected with wt and mutant viruses for 6, 12, 24, 30, and 36
h. Infectious virus was inactivated by acid treatment, the
acid was neutralized, and serial dilutions were incubated
with HeLa cells in 96-well plates overnight at 37 8C. To
construct a standard curve dose response, cells were
incubated with serial 5-fold dilutions of IFN (Universal
type I IFN, PBL Biomedical Laboratories, New Brunswick,
NJ). The samples were aspirated and cells were challenged
with wt VSV at 2.24  104 PFU/ml in 100 Al of media.
Controls included cells infected with VSV alone and cells
that were not challenged with VSV. Cells were incubated
overnight at 37 8C, media were aspirated, and cells were
fixed with 95% ethanol. Cells were then stained with a 0.1%
crystal violet solution in methanol. Absorbance was read at
550 nm on an ELISA reader. IFN levels greater than 150 IU/
ml were detectable by this bioassay. Data are the averages of
two independent experiments.
G protein surface expression
The efficiency of G protein cell surface expression
during VSV infection in LNCaP, PC-3, and benign prostate
cells was determined by flow cytometry analysis of infected
cells. Cells were seeded to approximately 70% confluence
in 35-mm dishes and infected with wt and mutant viruses at
a multiplicity of 10 pfu/ml for 4 and 8 h in RPMI containing
2% FBS for LNCaP and PC-3 cells, and MCDB complete
for benign prostate cells. Following infection, cells were
washed twice and then incubated for 1 h with 0.1 M
glycine–10% BSA in PBS at 4 8C. Surface-expressed G
protein was labeled with anti-G protein antibody I1
(Lefrancois and Lyles, 1982) at a 1:500 dilution for 1 h.
Cells were washed three times and incubated with a goat
anti-mouse immunoglobulin G secondary antibody conju-
gated to fluorescein (ICN Biomedicals, Inc.) at a dilution of
1:200 for 1 h at 4 8C. Cells were washed three times, fixed
for 10 min in 4% formaldehyde at 4 8C, and collected in 1
ml of 10% BSA. G protein cell surface fluorescence was
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cytometer.
Growth curves
LNCaP, PC-3, and benign prostatic cells in 35-mm dishes
were infected with viruses containing rwt or rM51R-M
viruses at a multiplicity of 10 pfu/cell (single step growth
curve) or 0.1 pfu/cell (multiple step growth curve) in RPMI
1640 containing 2% FBS (LNCaP and PC-3 cells) or
MCDB 105 complete (benign prostatic cells). At 1 h
postinfection, the media were aspirated, cells were washed
twice with PBS, and fed with 2 ml of the appropriate media.
At the indicated times postinfection, 100 Al of media was
removed from the dishes and stored at 70 8C. The yield of
virus was determined by plaque assays on BHK cells and
was expressed as pfu/ml.
Apoptosis assay
The percentage of infected cells undergoing DNA
fragmentation characteristic of apoptosis was determined
by TUNEL analysis (In Situ Cell Death Detection Kit;
Roche Diagnostics). LNCaP, PC-3, and benign prostate cells
were infected with rwt and rM51R-M viruses at a multi-
plicity of 10 pfu/cell. At 24 and 48 h postinfection, cells
were harvested, fixed in paraformaldehyde, and permeabi-
lized. Cells were incubated with the TUNEL reaction
mixture containing TdT and fluorescein-dUTP to free
3V0H ends in the DNA. The incorporated fluorescein was
analyzed and quantitated by flow cytometry on a Becton
Dickinson FACSCalibur flow cytometer.
Cell viability assay
LNCaP, PC-3, or benign prostate cells were infected with
wt and mutant viruses at an MOI of 0.1 or 10 pfu/cell. At
different times postinfection, live cells were measured by an
MTT assay (Cell Proliferation Kit 1; Roche Diagnostics)
according to the manufacturer’s instructions.
Tumor treatment
LNCaP and PC-3 cells were harvested from semi-
confluent cultures and cell viability was determined using
trypan blue exclusion. Cells with greater than 90%
viability were used for the experiments. Cells were
suspended at 2  106 cells/0.2 ml of ice-cold Matrigel
obtained from Collaborative Biomedical Products
(LNCaP), or in 0.2 ml of RPMI (PC-3 cells), and were
injected subcutaneously in the flank of BALB/c nude
mice. Animals were monitored for tumor development
three times a week by palpation of the injection site.
Animals with palpable tumors had their tumor volume
measured by calipers and the volume calculated using the
formula Volume = (width)2  length/2. At 3–4 weeksafter tumor cell injection, the tumor-bearing animals were
randomly separated into three experimental groups.
Animals were injected with VSV either intratumorally
(1  108 pfu) or intravenously (2  108 pfu) in culture
medium. Culture medium alone was used as negative
control. Tumor volume was measured daily with calipers,
as described above, and animal mass was also measured.
If the animals showed irreversible symptoms of VSV
infection (usually around 6 days postinfection) or signs of
end-stage illness as indicated by IACUC guidelines of
Wake Forest University Health Sciences, they were
sacrificed, and the tumor and selected tissues (brain,
lungs, spleen, and liver) were harvested for histological
analysis.
LD50 determination
Intranasal inoculation of 6-week-old BALB/c male mice
(Charles River Laboratories) with varying titers of wt and
mutant viruses was performed under anesthesia using
avertin (2,2,2 tribromoethanol and tert-amyl-OH). Two
separate experiments were conducted using five mice per
virus dose. For the first group, mice were inoculated with a
total volume of 20 Al containing 102–106 pfu of wtO, rwt,
and rM51R-M viruses. For the second group, mice were
infected with 105–107 pfu of rwt and 106–108 pfu of
rM51R-M viruses. Mice were monitored daily for signs of
VSV infection, such as hind limb paralysis. Upon signs of
end-stage illness, mice were sacrificed and tissue (brain,
lung, spleen, and liver) was harvested for histological
analysis.
Immunohistochemistry
Harvested tissues were fixed in 4% paraformaldehyde
overnight, embedded in paraffin, and sectioned at 5 Am.
Sections were stained with hematoxylin and eosin for
histological examination or used in immunohistochemical
staining. For immunohistochemical staining, cells were fixed
in descending series of ethanol washes, quenched with 0.3%
peroxide in PBS, and blocked in 5% goat serum. Serial
sections were incubated overnight with antibodies against the
viral envelope glycoprotein (rabbit anti-G, Research Diag-
nostics, Inc., Flanders, NJ). Secondary antibody (biotinylated
anti-rabbit from BioGenex Supersensitive kit) was incubated
on sections at room temperature for 30min. Primary antibody
detection was accomplished using a streptavidin alkaline
phosphatase detection kit (Supersensitive Detection Kit,
Biogenex, San Ramon, CA). Vector Red Substrate kit No.1
for alkaline phosphatase (Vector Laboratories, Inc., Burlin-
game, CA) was used to visualize the antibody–antigen
complex. Nuclei were counterstained using Mayers hema-
toxylin. Negative controls consisted of histologic sections
processed without the addition of primary antibody, but
incubated insteadwith 1% goat serum ormouse IgG (Reagent
Grade, 0.33 mg/ml, Sigma, Saint Louis, MO).
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Tissues from VSV-infected mice were harvested and
homogenized in media containing penicillin and streptomy-
cin. The homogenate (100 Al) was used to determine the
yield of virus by plaque assays on BHK cells. Data are the
average viral titers in tissue from two animals and are
expressed as pfu/tissue.
Statistical analysis
Chi-square tests of heterogeneity were used to test
whether there were significant differences in rate of death
after 14 days of exposure between wt and mutant viruses. To
account for the increased risk with increased dosage levels
and the fact that there were no observed deaths for rM51R-
M virus, a permutation-based test was used to evaluate the
statistical significance of the differences in the observed
rates of death. Specifically, for each pairing of viruses, a 2 
2 contingency table was constructed and a chi-square test
statistic was calculated from the observed data. Random
replicate data sets were generated by randomly permuting
deaths between viruses. To address the impact of different
dosages, we fixed the marginal counts of deaths and the
total number of observations for each virus at each dosage
level and randomly permuted deaths between two viruses at
each dosage level. Finally, a chi-square statistic was
constructed for each random replicate data set and a P
value was calculated as the proportion of random replicates
that had an equal or greater chi-square test statistic than the
observed test statistic.
We used mixed linear models (PROC MIXED; SAS
windows version 8, SAS Institute, Cary, N.C.) to assess
differences in tumor size overtime upon intratumoral treat-
ments. Data were used from three separate experiments,
which were treated as random effect in the models.
Specifically, we tested whether there were significant
differences in percent change, from baseline, of tumor size
between rwt and rM51R-M viruses after 7 and 14 days,
adjusting for experiment. We also tested whether changes in
tumor size were significant between 14 and 7 days for each
virus. Least square means were calculated for each virus
after 7 and 14 days.Acknowledgments
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